Showing 441-450 of 5361 results for "".
Manage and Prevent Isotretinoin Side Effects
https://practicaldermatology.com/topics/general-topics/PD0409_01-php/22839/This guide will help you anticipate and prevent or minimize side effects that your patients can develop as a result of isotretinoin therapy.Cosmetic Dermatology: Ensuring Success at Any Level
https://practicaldermatology.com/topics/general-topics/PD0409_02-php/22840/In practice and perspective, a balanced approach to cosmetic and medical affairs coupled with a strong team ensures effective implementation of cosmetic services.Ethics and Dermatology: Finding Harmony in Daily Practice
https://practicaldermatology.com/topics/general-topics/PD0109_06-php/22893/While there are no easy resolutions to ethical dilemmas, experts emphasize the importance of reflection and discussion in building higher ethical standards.A Picture is Worth 1,000 Words: Dermatology and eCOA Remote Image Capture Technology
https://practicaldermatology.com/topics/digital-practice/a-picture-is-worth-1000-words-dermatology-and-ecoa-remote-image-capture-technology/26955/A Picture is Worth 1,000 Words: Dermatology and eCOA Remote Image Capture TechnologyEnhancing Dermatopathologic Precision: Submitting Clinical Photographs with Biopsies Should Become Standard of Care in Difficult-to-Diagnose Cases
https://practicaldermatology.com/topics/editorial/enhancing-dermatopathologic-precision-submitting-clinical-photographs-with-biopsies-should-become-standard-of-care-in-difficult-to-diagnose-cases/26969/Enhancing Dermatopathologic Precision: Submitting Clinical Photographs with Biopsies Should Become Standard of Care in Difficult-to-Diagnose CasesOpen Payments Program: Does it Enhance Open Discussion About Financial Ties Between Dermatologists and Industry?
https://practicaldermatology.com/youngmd-connect/resident-resource-center/open-payments-program-does-it-enhance-open-discussion-about-financial-ties-between-dermatologists-and-industry/23619/The majority of physicians practicing in the United States have received some form of compensation from private industry during their careers. These payments may include consulting fees, compensation for speaking engagements, and stock options. Certain payments take indirect forms, such as physicDermWireTV: AcneAlly Launches, Rosacea Insights, MC2/EPI Collaboration
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-acneally-launches-rosacea-insights-mc2epi-collaboration/19849/Dennis Porto, MD and Riyaz Farhaad, MD have launched AcneAlly.com, an online service that allows patients access to a board certified dermatologist and a standardized approach to assessment and long-term monitoring. Julie Harper, MD discusses findings from “Beyond the visible: Rosacea and psoriasisDermWireTV: Noble Educates on Self-Injection; AAD and DEF Meeting Updates
https://practicaldermatology.com/topics/practice-management/dermwiretv-noble-educates-on-self-injection-aad-and-def-meeting-updates/19645/Participants in a study by the company Noble show that the vast majority of patients—92%—would prefer to bring home a training device to practice with prior to starting self-injection. Noble creates trainers for autoinjectors intended to increase patient confidence and autonomy with self-managed treOn the Leading Edge, Not the Bleeding Edge: Joe Niamtu, DMD
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/on-the-leading-edge-not-the-bleeding-edge-joe-niamtu-dmd/18606/Innovator, influencer, and podium perennial Joe Niatmu, III, DMD has built a successful surgical aesthetic practice by focusing on the basics, concentrating on his strengths, and avoiding passing fads. How does he stay passionate, spot the best new developments, and build a fulfilling practice? In tDermWireTV: Spevigo for GPP; Derms on Acne Experience; IFPA Takes PsO to the Gaming World; La Roche-Posay at the US Open
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-spevigo-for-gpp-derms-on-acne-experience-ifpa-takes-pso-to-the-gaming-world-la-roche-posay-at-the-us-open/20136/Boehringer Ingelheim’s Spevigo is the first FDA-approved treatment option for generalized pustular psoriasis (GPP) flares in adults. Spesolimab is a novel, selective antibody that blocks the activation of the interleukin-36 receptor. Dermatologists, dermatology physician assistants, and dermatology